$80.00
The premier melanocortin receptor agonist revolutionizing the scientific study of desire, arousal, and central nervous system signaling. Unlike standard peripheral vasodilators, this innovative peptide targets the true source of physiological response—the brain—unlocking entirely new research pathways into libido stimulation, neuro-activation, and enhanced sexual wellness. Whether you are exploring complex behavioral models or investigating synergistic therapies for non-responders, our ultra-pure, HPLC-verified PT-141 delivers the uncompromised potency, elite consistency, and laboratory reliability your most visionary experiments demand.
Per vial
Form
Purity
CAS #
Molecular Formula
Molecular Weight
Half-life
Origin
Development Stage
Mechanism
Advanced Central Nervous System Melanocortin & Arousal Research
Explore the neurological pathways of desire, arousal, and behavioral endocrinology with PT-141 (Bremelanotide) 10 MG, an elite-tier synthetic cyclic heptapeptide engineered for advanced melanocortin receptor research. Originally developed from the alpha-melanocyte-stimulating hormone ($\alpha$-MSH) peptide metabolite MT-II, Bremelanotide is structurally optimized without the heavy C-terminal amide group, retaining potent central nervous system activity while significantly minimizing off-target melanogenic (tanning) stimulation.
Unlike conventional phosphodiesterase type 5 (PDE-5) inhibitors that operate strictly through peripheral vascular vasodilation, PT-141 binds directly to MC4R and MC3R receptors in the hypothalamus. This central mechanism of action allows researchers to investigate the neurological initiation of sexual desire, dopamine-associated arousal circuitry, and pro-erectile nerve signaling independently of localized blood flow limitations.
Central Nervous System Target: Binds with high affinity to hypothalamic melanocortin receptors (MC4R and MC3R), making it an ideal model for studying brain-centered arousal and sexual desire pathways.
Non-Vascular Mechanism: Initiates physiological and behavioral arousal via neural signaling rather than direct vascular hemodynamics, offering an alternative research pathway for non-responders to traditional PDE-5 inhibitors.
Cyclic Peptide Stability: Features a rigid cyclic lactam structure between the Asp and Lys residues, providing exceptional resistance to enzymatic degradation and ensuring a predictable 2.7-hour biological half-life.
Synergistic Research Potential: Extensively validated in literature for co-administration studies alongside PDE-5 inhibitors, demonstrating amplified, statistically significant pro-erectile responses in challenging clinical models.
Behavioral & Endocrinological Applications: Valuable for investigating dopamine release mechanisms, energy expenditure, appetite regulation, and neuro-activation within the paraventricular nucleus.
Ultra-Pure Specification: Lyophilized and synthesized at an elite $\ge 99\%$ purity level (HPLC and Mass Spectrometry verified) to ensure absolute precision and zero contaminant interference in sensitive laboratory assays.
This product is intended for laboratory research use only (RUO). Not for human or veterinary use.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Peak Vitality peptides have not been approved by Health Canada. Products by Peak Vitality have not been assessed for safety, efficacy and/or quality, may pose a range of serious health risks, and are intended for research purposes only. Products sold under Peak Vitality are not intended to treat, cure, or prevent diseases and/or conditions and may cause serious side effects.